U.S. markets open in 16 minutes
  • S&P Futures

    3,881.00
    -41.75 (-1.06%)
     
  • Dow Futures

    31,093.00
    -347.00 (-1.10%)
     
  • Nasdaq Futures

    11,826.00
    -109.50 (-0.92%)
     
  • Russell 2000 Futures

    1,756.80
    -16.00 (-0.90%)
     
  • Crude Oil

    105.72
    -3.87 (-3.53%)
     
  • Gold

    1,837.40
    +21.50 (+1.18%)
     
  • Silver

    21.42
    -0.11 (-0.50%)
     
  • EUR/USD

    1.0555
    +0.0089 (+0.85%)
     
  • 10-Yr Bond

    2.7760
    -0.1100 (-3.81%)
     
  • Vix

    32.01
    +5.91 (+22.64%)
     
  • GBP/USD

    1.2446
    +0.0104 (+0.85%)
     
  • USD/JPY

    127.2270
    -1.0700 (-0.83%)
     
  • BTC-USD

    29,625.04
    +74.70 (+0.25%)
     
  • CMC Crypto 200

    658.57
    -12.11 (-1.81%)
     
  • FTSE 100

    7,260.40
    -177.69 (-2.39%)
     
  • Nikkei 225

    26,402.84
    -508.36 (-1.89%)
     

What You Need To Know About Cardiol Therapeutics Inc.'s (TSE:CRDL) Investor Composition

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

The big shareholder groups in Cardiol Therapeutics Inc. (TSE:CRDL) have power over the company. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. I quite like to see at least a little bit of insider ownership. As Charlie Munger said 'Show me the incentive and I will show you the outcome.

Cardiol Therapeutics is not a large company by global standards. It has a market capitalization of CA$192m, which means it wouldn't have the attention of many institutional investors. Our analysis of the ownership of the company, below, shows that institutions own shares in the company. Let's delve deeper into each type of owner, to discover more about Cardiol Therapeutics.

View our latest analysis for Cardiol Therapeutics

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Cardiol Therapeutics?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

We can see that Cardiol Therapeutics does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Cardiol Therapeutics' earnings history below. Of course, the future is what really matters.

earnings-and-revenue-growth
earnings-and-revenue-growth

We note that hedge funds don't have a meaningful investment in Cardiol Therapeutics. Looking at our data, we can see that the largest shareholder is the CEO David Elsley with 4.0% of shares outstanding. With 2.9% and 2.7% of the shares outstanding respectively, Eldon Smith and Mirae Asset Global Investments Co., Ltd are the second and third largest shareholders.

On studying our ownership data, we found that 24 of the top shareholders collectively own less than 50% of the share register, implying that no single individual has a majority interest.

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.

Insider Ownership Of Cardiol Therapeutics

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

Our most recent data indicates that insiders own some shares in Cardiol Therapeutics Inc.. It has a market capitalization of just CA$192m, and insiders have CA$14m worth of shares, in their own names. It is good to see some investment by insiders, but I usually like to see higher insider holdings. It might be worth checking if those insiders have been buying.

General Public Ownership

The general public holds a substantial 58% stake in Cardiol Therapeutics, suggesting it is a fairly popular stock. This size of ownership gives investors from the general public some collective power. They can and probably do influence decisions on executive compensation, dividend policies and proposed business acquisitions.

Next Steps:

It's always worth thinking about the different groups who own shares in a company. But to understand Cardiol Therapeutics better, we need to consider many other factors. Case in point: We've spotted 4 warning signs for Cardiol Therapeutics you should be aware of, and 2 of them are significant.

But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.